中国人用疫苗上市情况分析与展望  

Marketing and prospects for human vaccines in China

作　　者：王冠杰 邵明立[1,3] Wang Guanjie;Shao Mingli(Shenyang Pharmaceutical University,Shenyang 110016,Liaoning,China;National Institute for Food and Drug Control,Beijing 102629,China;China Society for Drug Regulation,Beijing 100082,China)

机构地区：[1]沈阳药科大学,辽宁沈阳110016 [2]中国食品药品检定研究院,北京102629 [3]中国药品监督管理研究会,北京100082

出　　处：《中国疫苗和免疫》2021年第1期116-120,共5页Chinese Journal of Vaccines and Immunization

摘　　要：本文分析了中国2019年批签发的人用疫苗种类、数量、生产企业等,对比了国内外疫苗行业发展趋势,展望了中国疫苗发展前景。中国免疫规划疫苗发展平稳,非免疫规划疫苗有较大发展空间,多联多价疫苗、治疗性疫苗和应急疫苗发展迅速。中国需鼓励疫苗产业研发与生产,进一步提高疫苗上市后的安全、有效和合理可及性。In this article,we analyze types,quantities,and manufacturers of human vaccines that were released for Chinese markets in 2019;we compare development trends of Chinese and international vaccines and discuss prospects for development of Chinese vaccines.In China,National Immunization Program(NIP)vaccines maintain steady development while non-NIP vaccines have a larger development space;combination or multivalent vaccines,therapeutic vaccines,and emergency vaccines are developed rapidly.The Chinese government should encourage vaccine manufacturers to conduct research and develop vaccines to improve safety,effectiveness and accessibility of vaccines during post-marketing periods.

关 键 词：疫苗 批签发 上市 展望 

分 类 号：R186[医药卫生—流行病学]